Site hosted by Angelfire.com: Build your free website today!
Title: US5824650: Topical composition containing a substance P antagoinst
Inventor(s): De Lacharriere; Olivier , Paris, France
Breton; Lionel , Versailles, France
View Images High
Resolution

 Low
 Resolution

 
6 pages
Applicant/AssigneeInquire Regarding Licensing: L'Oreal, Paris, France
other patents from L'OREAL S.A. (approx. 2, 410)
News, Profiles, Stocks and More about this company
Issued/Filed Dates: Oct. 20, 1998 / Dec. 19, 1995
Application Number: US1995000575682
IPC Class: A61K 38/00; A61K 31/135;
ECLA Code: A61K38/08+M; A61K38/04T; A61K31/19+M; A61K31/20T+M;
Class: Current: 514/015; 514/167; 514/210; 514/210.03; 514/252.04; 514/293; 514/305; 514/315; 514/410; 514/416; 514/422; 514/423; 514/426; 514/438; 514/461; 514/613; 514/617; 514/646; 514/663;
Original: 514/015; 514/210; 514/293; 514/305; 514/315; 514/410; 514/416; 514/422; 514/423; 514/426; 514/438; 514/461; 514/613; 514/617; 514/663; 514/646;
Field of Search: 514/15,646
Priority Number(s):
Dec. 19, 1994  FR1994000015253

Legal Status: Show legal status actions
Abstract:

$10 Off Handcrafted Plaques from Patent Awards:

 The invention relates to a therapeutic composition for topical application containing at least one product with an irritant side effect and a substance P antagonist for reducing or even eliminating the irritant effect of this product. It also relates to the use of a substance P antagonist for the preparation of a pharmaceutical composition for topical application containing at least one product with an irritant side effect for reducing or even eliminating the irritant effect of this product. The substance P antagonist may be a peptide compound or a nitrogen-containing compound or a nitrogen-, sulphur- or oxygen-containing heterocyclic compound.
Attorney, Agent, or Firm: Burns, Doane, Swecker & Mathis, L.L.P.;
Primary/Assistant Examiners: Cook; Rebecca;
Family: Show known family members
Forward References: Show the 5 patents that reference this one
             

U.S. References:
Patent   Issued   Inventor(s) Applicant/Assignee   Title
US3772431 11 /1973 Mlkvy et al.   EFFERVESCENT MOUTHWASH TABLET
US3888976 6 /1975 Mlkvy et al.   Zinc and strontium ion containing effervescent mouthwash tablet
US4477439 10 /1984 D'Alelio  Monacelli; Walter J. Treatment of irritated and excoriated areas around the stoma of ostomy patients
US4943432 7 /1990 Biener   Salt mixture for the treatment of psoriasis
US4980184 12 /1990 Gordon  Boliden Kemi Aktiebolag Method and agent for preservation of hay
US4986981 1 /1991 Glace et al.  Den Mat Corporation Toothpaste having low abrasion
US5047409 9 /1991 Di Schiena et al.  Serono OTC S.A. Compounds for cosmetic-dermatological use and relevant compositions
US5079010 1 /1992 Natterer   Pharmaceutical preparation for the treatment of wounds, damaged tissue and inflammation in animals
US5091171 2 /1992 Yu et al.   Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
US5202130 4 /1993 Grant et al.  The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
US5569662 10 /1996 Satake et al.  Pfizer Inc. Quinuclidine derivatives as substance P antagonists


             
First Claim: Show all 16 claims

We claim:
    1. A method of treating or preventing irritation to sensitive skin which occurs upon topical administration of at least one product which normally elicits an irritant side effect to sensitive skin if topically administered in the absence of an effective amount of a substance P antagonist, which comprises topically administering to a subject having sensitive skin a composition comprising (i) said product which normally elicits an irritant side effect, upon topical application to sensitive skin (ii) an amount of at least one substance P antagonist sufficient to reduce or eliminate said irritant side effect, and (iii) a pharmaceutically acceptable medium.
Background/Summary: Show background/summary
Drawing Descriptions: Show drawing descriptions
Description of Preferred Embodiments: Show description of preferred embodiments
Foreign References:
Publication Country Date IPC Class
EP1987000217975 European Patent Office (EPO) 4 /1987  
EP1991000439640 European Patent Office (EPO) 8 /1991  
EP1991000459890 European Patent Office (EPO) 12 /1991  
EP1994000586929 European Patent Office (EPO) 3 /1994  
FR1967000005394 France 10 /1967  
FR1978002184890 France 6 /1978  
DE1985003338957 Germany 5 /1985  
DE1990000280692 Germany 7 /1990  
DE1992000297062 Germany 1 /1992  
WO1996WO0019184 World Intellectual Property Organization (WIPO) 6 /1996  


Other Abstract Info: CHEMABS 125(12)151165H DERABS C96-311244
Other References:
Article info links by
ISI logo
:
  • Exp Eye Res, 50(1). 1990. 21-26, Beding-Barnekow et al, "Systemic and Intraocular . . . ", p. 25, col. 2, line 2. (6 pages)
  • Eur. J. Pharmacol., 1991, 209/3 (175-183), Netherlands, Andersson et al, "Ruthenium Red . . . ". (9 pages) 3 patents reference this [Article Info]
  • Br J. Dermatol, 124 (4). 1991. 324-328., Wallengren, "Substance P Antagonist . . . ". (5 pages) 10 patents reference this [Article Info]
  • Jancso-Gabor, "Action of rare earth metal complexes on neurogenic as well as on bradykinin-induced inflammation", J. Pharm. Pharmac.,22:366-371 (1970).
  • "La peau sensible, un authentique syndrome clinique", Le Quotidien du Medecin, No. 5747, Dec. 6, 1995; Cosmetologie, Therapeutique, No. 1511, Dec. 17, 1995.
  • Uy Dong Sohn et al, "Agonist-Independent, Muscle-Type-Specific Signal Transduction Pathways in Cat Esophageal and Lower Esophageal Sphincter Circular Smooth Muscle", J. of Pharmacology & Experimental Therapeutics,273:481-491 (1995).
  • Mitsuo Ishizawa, "Contractile Responses of Longitudinal Muscle Strip to 5-HT and Influences of Divalent Cations in the Guinea-Pig Isolated Colon", J. Smooth Muscle Res., 30:65-72 (1994).
  • H. Goodman, Cosmetic Dermatology, First Edition, Fourth Impression, p. 181 (1936).
  • Martindale, The Extra Pharmacopoeia, Twenty-seventh Edition, The Pharmaceutical Press, London, pp. 219, 1775 and 1814 (1977).
  • McGraw-Hill Dictionary of Scientific and Technical Terms, Fifth Edition, pp. 109 and 332 1995.
  • Sohn et al, Different Receptors Activate a Different Single G-Protein in Esophageal. (Gis) and in LES (Gq) Circular Smooth Muscle, Gastroenterology, vol. 104 (1993).
  • Maison G. deNavarre, The Chemistry and Manufacture of Cosmetics, 2nd Ed. vol. IV, p. 1261 (1975).
  • Alexander A. Fisher, "Irritant Reactions from Topical Urea Preparations Used for Dry Skin Advantages of a Urea-Free `Dead Sea Salt`Cream", Current Contact News, vol. 18, pp. 761-772 (1976).
  • The United States Pharmacopeia, "Alumina/Drug Substances and Dosage Form", pp. 20 and 22 (1975).
  • Nordia Briefs, "A Salt-Containing Cream for Dry Skin", No. 484, Jan. 1978.
  • Cosmetic Counter, vol. 109, Oct. 1994.
  (To sort a column, click sort arrow) 417 patents matched 
 Score
US05683725 11/04/1997 Modulation of substance P by compounds containing calcium sulfate and methods relating thereto 97%
US05525712 06/11/1996 DNA encoding the human neurokinin-1 receptor 96%
US05484886 01/16/1996 Human neurokinin-1 receptor 96%
US05945508 08/31/1999 Substance P treatment for immunostimulation 94%
US06258943 07/10/2001 Human neurokinin-3 receptor 92%
US05410019 04/25/1995 Therapeutic peptides 91%
US05998376 12/07/1999 Substance P treatment for immunostimulation 90%
US05616562 04/01/1997 Methods and compositions using substance P to promote wound healing 90%
US05560915 10/01/1996 Composition for treating IgE mediated allergies comprising substance P and allergen 90%
US05762963 06/09/1998 Method and compositions for controlling oral and pharyngeal pain using capsaicinoids 89%
US05314690 05/24/1994 Method and composition for treating IgE-mediated allergies 89%
US06156725 12/05/2000 Drug for the treatment of cancer 88%
US05624893 04/29/1997 Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation 88%
US04481139 11/06/1984 Peptide antagonists of substance P 88%
US06262243 07/17/2001 Nucleic acids encoding antimicrobial peptides 87%
US06040316 03/21/2000 3-alkyl-3-phenyl-piperidines 87%
US05861416 01/19/1999 Substituted pyrrolidin-3-yl-alkyl-piperidines 85%
US05824650 10/20/1998 Topical composition containing a substance P antagoinst 85%
US05736517 04/07/1998 Treatment of cancer with peptides 85%
US05217955 06/08/1993 Treatment of cancer with peptide analog of bombesin, GRP, litorin or neuromedin
Title: US5683725: Modulation of substance P by compounds containing calcium sulfate and methods relating thereto
Inventor(s): Malik; Sohail , Seattle, WA
Hebert; Rolland F. , Bellevue, WA
Yee; Min , Bellevue, WA
View Images High
Resolution

 Low
 Resolution

 
14 pages
Applicant/AssigneeInquire Regarding Licensing: BioFrontiers, Inc., Bellevue, WA
other patents from BIOFRONTIERS, INC. (approx. 1)
News, Profiles, Stocks and More about this company
Issued/Filed Dates: Nov. 4, 1997 / May 25, 1995
Application Number: US1995000449949
IPC Class: A61K 33/04; A61K 33/06;
ECLA Code: A61K33/06;
Class: Current: 424/696; 424/682; 424/709;
Original: 424/696; 424/682; 424/709;
Field of Search: 424/696,709,682
Legal Status: Show legal status actions
Abstract:

$10 Off Handcrafted Plaques from Patent Awards:

 Modulation of substance P by compounds containing calcium sulfate is disclosed. Preferred calcium sulfate compounds include syngenite, gorgeyite and gypsum. Methods of this invention include the modulation of substance P, as well as methods for preventing or treating conditions associated with substance P, by administering to an animal an effective amount of a calcium sulfate compound. Conditions associated with substance P include headaches and migraine, neurogenic inflammation, emesis, nausea and vomiting, cough and bronchitis, obesity, allergy, asthma, hemorrhoids and anal fissures, ulcer, fever, infertility and periodontal disease.
Attorney, Agent, or Firm: Seed and Berry LLP;
Primary/Assistant Examiners: Pak; John;
Family: Show known family members
Forward References: Show the 3 patents that reference this one
             

U.S. References:
Patent   Issued   Inventor(s) Applicant/Assignee   Title
US4554139 11 /1985 Worthington et al.  Prodeco, Inc. Process for producing and decomposing syngenite
US4689223 8 /1987 Arias  T & R Chemicals, Inc. Method of treating the symptoms of the common cold
US4735802 4 /1988 Le   Topical dermatological composition and method of treatment
US4915936 4 /1990 Patterson et al.  United States Gypsum Company Dental hygiene composition for reducing periodontal disease


             
First Claim: Show all 16 claims

We claim:
    1. A method for inhibiting substance P in a warm-blooded animal, comprising administering to an animal in need thereof an effective amount of gorgeyite.
Background/Summary: Show background/summary
Drawing Descriptions: Show drawing descriptions
Description of Preferred Embodiments: Show description of preferred embodiments
Foreign References:
Publication Country Date IPC Class
WO08809665 World Intellectual Property Organization (WIPO) 12 /1988  
WO09409798 World Intellectual Property Organization (WIPO) 5 /1994  
WO09505752 World Intellectual Property Organization (WIPO) 3 /1995  


Other Abstract Info: CHEMABS 126(06)079955S DERABS C97-020927
Other References:
Article info links by
ISI logo
:
  • Derwent Abstracts, Accession No. 96-246881 C25, 1996, Abstracting JP 8099848 (Apr. 16, 1996).
  • Bartold et al., "Substance P: An Immunohistochemical and Biochemical Study in Human Gingival Tissues. A Role for Neurogenic Inflammation?," J. Periodontol 65:1113-1121 (1994). (9 pages) [Article Info]
  • Gyorfi et al., "Role of substance P (SP) in development of symptoms of neurogenic inflammation in the oral mucosa of the rat," J. Periodont Res 28:191-196 (1993). (6 pages) [Article Info]
  • Joos et al., "Sensory neuropeptides and the human lower airways: present state and future directions," Eur. Respir. J. 7:1161-1171 (1994). (11 pages) [Article Info]
  • Sestini et al., "Ion Transport in Rat Tracheal Epithelium In Vitro. Role of Capsaicin-sensitive Nerves in Allergic Reactions," AM Rev Respir 141:393-397 (1990). (5 pages)
  • Nakai et al., "Substance P-induced cutaneous and bronchial reactions in children with bronchial asthma," Ann. Allergy 66:155-161 (1991). (7 pages) [Article Info]
  • Hagiwara et al., "Studies on Neurokinin Antagonists. 4. Synthesis and Structure-Activity Relationships of Novel Dipeptide Substance P Antagonists: N2 -[(4R)-4-Hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-prolyl]-N-methyl-N-(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and Its Related Compounds." J. Med. Chem. 37:2090-2099 (1994). (10 pages) [Article Info]
  • Wallengren, J., "Substance P antagonist inhibits immediate and delayed type cutaneous hypersensitivity reactions," Br. J Derm. 124:324-328 (1991). (5 pages) 10 patents reference this [Article Info]
  • Felten et al., "Fundamental Aspects of Neural-Immune Signaling," Psycother. Psychosom. 60:46-56 (1993). (11 pages) [Article Info]
  • Lee et al., "Blockade by Oral or Parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva," Br. J. Pharmacol. 112:920-924 (1994). (5 pages) [Article Info]
  • Liu et al., "The effects of capsaicin on pulpal blood flow," Proc. Finn. Dent. Soc. 88(Supp. I):463-467 (1992).
  • Nieber et al., "The Possible Role of Substance P in the Allergic Reaction, Based on Two Different Provocation Models," Int. Arch. Allergy Appl. Immunol. 94:334-338 (1991). (5 pages) [Article Info]
  • Okamoto et al., "Cytokine Expression After the Topical Administration of Substance P to Human Nasal Mucosa. The Role of Substance P in Nasal Allergy," J. Immunol. 151:4391-4398 (1993). (8 pages) [Article Info]
  • Rameshwar et al., "In Vitro Stimulatory Effect of Substance P on Hematopoiesis." Blood 81:391-398 (1993). (8 pages) [Article Info]
  • Alleva et al., "Capsaicin Affects Aggressive Behavior, But Not Hot Plate Responding, of Adult Male Mice," Physiology & Behavior 49:715-719 (1991). (5 pages) [Article Info]
  • Crimi et al., "Influence of antihistamine (astemizole) and anticholinergic drugs (ipratropium bromide) on bronchoconstriction induced by substance P," Ann. Allergy 65:115-120 (1990). (6 pages)
  • Elliot et al., "Modulation of the rat mesolimbic dopamine pathway by neurokinins," Behavioural Brain Research 51:77-82 (1992). (6 pages) [Article Info]
  • Evangelista et al., "Duodenal SP-like immunoreactivity is decreased in experimentally-induced duodenal ulcers," Neuroscience Letters 112:352-355 (1990). (4 pages)
  • Malek-Ahmadi, P., "Substance P and Neuropsychiatric Disorders: An Overview," Neuroscience and Biobehavioral Reviews 16:365-369 (1992). (5 pages) 13 patents reference this [Article Info]
  • Moore & Black, "Neuropeptides," Neurosurg. Rev. 14:97-110 (1991). (14 pages) [Article Info]
  • Moussaoui et al., "Inhibition of neurogenic inflammation in the meninges by a non-peptide NK1 Receptor Antagonist, RP 67580," Eur. J. Pharma. 238:421-424 (1993). (4 pages) 2 patents reference this [Article Info]
  • Shuster, S., "Capsaicin and the cause of causalgia," Lancet 345:160-161 (1995). (2 pages) [Article Info]
  • Tsuji and Cook, "Origin of thromboxane-mediated constriction due to neuropeptides in canine basilar artery," Eur. J Pharma. 264:77-80 (1994). (4 pages) [Article Info]
  • Dockray, G., "Substance P and Other Tachykinins," in Gut Peptides: Biochemistry and Physiology, Raven Press, New York, N.Y. 1994 (edited by John Walsh and Graham Dockray), pp. 401-422.
  • Dryden et al., "Neuropeptide Y and energy balance: one way ahead for the treatment of obesity?" Eur. J Clin. Invest. 24:293-308 (1994). (16 pages) [Article Info]
  • Paus et al., "Hair Growth Induction by Substance P," Lab. Invest. 71:134-140 (1994). (7 pages) 3 patents reference this [Article Info]
  • Talley et al., "GR 38032F (Ondansetron), A Selective 5HT3 Receptor Antagonist, Slows Colonic Transit in Healthy Man," Digestive Diseases and Sciences 35:477-480 (1990). (4 pages)
  • Karlberg, B., "Cough and inhibition of the renin-angiotensin system," Journal of Hypertension 11(supp.3):S49-S52 (1993). (4 pages) [Article Info]
  • Blatteis, "Role of the OVLT in the febrile response to circulating pyrogens," Progress in Brain Research 91:409-412 (1992). (4 pages) [Article Info]
  • Nadel, J., "Mechanisms of Inflammation and Potential Role in the Pathogenesis of Asthma," Allergy Proc. 12:85-88 (1991). (4 pages) [Article Info]
  • Williams et al., "Reduced Hypothalamic Neurotensin Concentrations in the Genetically Obese Diabetic (ob/ob) Mouse: Possible Relationship to Obesity," Metabolism 40:1112-1116 (1991). (5 pages) [Article Info]
  • Blatteis et al., "Neuromodulation of Fever. A Possible Role for Substance P," Ann. N.Y. Acad. Sci. 741:162-173 (1992).
  • Gyorfi et al., "Neurogenic inflammation and the oral mucosa," J. Clin Periodontol 19:731-736 (1992). (6 pages) [Article Info]
  • Ohkubo et al., "Role of Substance P in Neurogenic Inflammation in the Rat Incisor Pulp and the Lower Lip," Archs oral Biol. 38:151-158 (1993). (8 pages) [Article Info]
  • Schmid et al., "Temperature sensitivity of neurons in slices of the rat PO/AH area: effect of bombesin and substance P," Am. J. Physiol. 264:R449-R455 (1993). (7 pages) [Article Info]
  • Barnes, R., "Neurogenic Inflammation and Asthma," Journal of Asthma 29:165-180 (1992). (16 pages) [Article Info]
  • Mosimann et al., "Allergens, IgE, mediators, inflammatory mechanisms. Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients," J Allergy Clin Immunol 92:95-104 (1993). (10 pages) [Article Info]
  • Debeljuk and Bartke, "Immunoreactive Substance P and Neurokinin A in the Hypothalamus and Anterior Pituitary Gland of Siberian and Syrian Hamsters and of Rats," J Reproduction and Fertility 101:427-434 (1994). (8 pages) [Article Info]
  • Chiwakata et al., "Tachykinin (Substance-P) Gene Expression in Leydig Cells of the Human and Mouse Testis," Endocrinology 128:2441-2448 (1991). (8 pages) [Article Info]
  • Kerdelhue et al., "Hypothalamo-Anterior Pituitary Gonadotropin-Releasing Hormone and Substance-P Systems during the 17ß-Estradiol-Induced Plasma Luteinizing Hormone Surge in the Ovariectomized Female Monkey," Endocrinology 132:1151-1157 (1993). (7 pages) [Article Info]

Search http://www.delphion.com/